Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Antihypertensives: Generics striking at heart of the market

08 Dec 06

Despite almost 200 million people suffering from high blood pressure in the western world alone, the growth rate of the antihypertensive market is actually slowing, largely as a result of generic incursion. In fact many pharmaceutical companies, including those with strong cardiovascular portfolios, are turning their back on this market in favor of more profitable indications, such as oncology.
Datamonitor

AstraZeneca has announced that it will launch a generic version of its own heart drug Toprol XL.

24 Nov 06

AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry.
Datamonitor

Inhalable insulin: reality doesn't live up to hype

21 Nov 06

Inhalabe insulin treatments promised to revolutionize the treatment of insulin-dependent diabetes by removing the 'injection barrier' from treatment regimes. However, while inhalable insulins will see a reasonable level of uptake, they aren't the sure fire blockbuster they were hyped to be.
Datamonitor

Asthma/COPD combination products here to stay

10 Nov 06

The treatment of asthma and COPD has dramatically improved following the increased use of fixed dose inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination therapies. Although Advair dominates the total asthma/COPD market, Symbicort's recent US approval and Chiesi's recent European approval of an ICS/LABA combination drug, signal a major change in the market dynamics.
Datamonitor

Pfizer: still biggest player in highly prized indication

31 Oct 06

The success of neuropathic pain drug Neurontin earned Pfizer its reputation as the "neuropathic pain company" and the US pharmaceutical giant faced very little competition in a relatively untapped market for ten years. Neuropathic pain is now one of the most attractive indications in the pharmaceutical industry but Pfizer still dominates the market.
Datamonitor

The PharmiWeb.com e:HR Awards 2006

25 Oct 06

Recognizing excellence in the application of an e-business approach in pharma and biotech HR in Europe.
Mike Wood

Drug pipeline suggests glimmer of hope for SLE sufferers

20 Oct 06

While there have been no new treatments approved for systemic lupus erythematosus (SLE) in almost 40 years, there are some promising treatments currently in the development pipeline. Unfortunately, the ambiguity surrounding the requirements of clinical trials is preventing these drugs from being approved. However, faced with few alternatives, that hasn't prevented physicians using them off-label.
Datamonitor

Has the current approach to pharmaceutical sales passed its expiry date?

17 Oct 06

It’s another Monday practice meeting, the usual drug representative has been roped in to provide lunch and is cooling her heels waiting for the team to finish morning surgery. The usual non-descript pile of sandwiches from the local bakery is stacked on the table and the registrar who has finished early has already picked the best sandwiches...
Ian Mckenzie - PharmiWeb.com Field Reporter

Ovarian cancer: platinum-based therapy still the gold standard

13 Oct 06

Despite being the most common cause of death from gynecological tumors, ovarian cancer does not attract the same level of R&D interest as more prevalent tumor types. While surgery still plays a central role in the treatment of ovarian cancer, platinum-based therapy, in particular, carboplatin in combination with paclitaxel, remains the mainstay of cytotoxic treatment for ovarian cancer.
Datamonitor

Schering-Plough: new fungicide gets US approval

06 Oct 06

Noxafil is a new fungicide developed by Schering-Plough. Already marketed in Europe, it has now received US approval on the basis of clinical trials showing its superiority over fluconazole in preventing invasive fungal infections in immuno-compromised patients. Revenues derived from this new drug will help bolster Schering-Plough's Infectious Diseases division.
Datamonitor

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.